ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In another impressive first round of funding for a New York City biotech firm, Prevail Therapeutics has raised a $75 million series A. Prevail launched with seed funding last year to develop adeno-associated virus (AAV)-based gene therapies for neurodegenerative diseases related to lysosomal dysfunction, including a subset of Parkinson’s disease. Prevail will use Regenxbio’s AAV9 vector, which targets the nervous system.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter